Sofosbuvir (Sovaldi) falls under the nucleotide analog family of medication, which works in order to block the hepatitis C NS5B protein.
In the year of 2007, Sofosbuvir was originated by Michael Sofia, a scientist at Pharmasset, and in the year of 2010, it was first tested in people.
In the year of 2011 Gilead Sciences bought Pharmasset for around $11 billion. In the month of April, 2013, Gilead submitted the New Drug Application for sofosbuvir along with ribavirin.
In the month of October, 2013, it received the Food and Drug Administration's breakthrough therapy designation.
In the month of December, 2013, the Food and Drug Administration approved sofosbuvir along with ribavirin for the oral dual therapy of the HCV genotypes-2 & 3, and for the triple therapy with the injected pegylated interferon (pegIFN) and RBV for the treatment-naive individuals with HCV genotypes-1 & 4.
In the year of 2014 the fixed dose combination medication sofosbuvir/ledipasvir, the latter a viral NS5A inhibitor, was approved; it had also been granted the breakthrough status.
The U.S. launch of Sofosbuvir was the fastest of any new medication in history.
The sofosbuvir 400 mg price in india is around 23,571 INR for a supply of 28 tablets, depending on the wholesaler/pharmacy you visit. Any WHO-GDP & ISO certified pharmaceutical wholesaler company would be best to buy Sofosbuvir.
